Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Sci Rep ; 13(1): 6329, 2023 Apr 18.
Article in English | MEDLINE | ID: mdl-37072434

ABSTRACT

Conventional crop height measurements performed using aerial drone images require 3D reconstruction results of several aerial images obtained through structure from motion. Therefore, they require extensive computation time and their measurement accuracy is not high; if the 3D reconstruction result fails, several aerial photos must be captured again. To overcome these challenges, this study proposes a high-precision measurement method that uses a drone equipped with a monocular camera and real-time kinematic global navigation satellite system (RTK-GNSS) for real-time processing. This method performs high-precision stereo matching based on long-baseline lengths (approximately 1 m) during the flight by linking the RTK-GNSS and aerial image capture points. As the baseline length of a typical stereo camera is fixed, once the camera is calibrated on the ground, it does not need to be calibrated again during the flight. However, the proposed system requires quick calibration in flight because the baseline length is not fixed. A new calibration method that is based on zero-mean normalized cross-correlation and two stages least square method, is proposed to further improve the accuracy and stereo matching speed. The proposed method was compared with two conventional methods in natural world environments. It was observed that error rates reduced by 62.2% and 69.4%, for flight altitudes between 10 and 20 m respectively. Moreover, a depth resolution of 1.6 mm and reduction of 44.4% and 63.0% in the error rates were achieved at an altitude of 4.1 m, and the execution time was 88 ms for images with a size of 5472 × 3468 pixels, which is sufficiently fast for real-time measurement.

2.
Sci Rep ; 12(1): 21147, 2022 Dec 07.
Article in English | MEDLINE | ID: mdl-36476641

ABSTRACT

This paper attempts to extend the concept of the equilibrium point to what is called equilibrium space, which can adapt to a system in which there exists an infinite number of equilibrium points. In the context of Lyapunov's linearization method extended for the equilibrium space, this paper proposes a pseudo linearization, from which we can derive a linear representation for a nonlinear system. The equilibrium state of this pseudo linearization and its stability are shown to be the same as that of the original nonlinear system. As an example of the applicability, the proposed pseudo linearization is applied to derive a discrete-time model for a control moment gyroscope system from a nonlinear continuous-time model. Simulation results show that the discrete-time model derived using the proposed pseudo linearization yields responses that are closer to that of the continuous-time model than the discrete-time model derived by the well-known forward-difference method and the conventional pseudo linear representation method, even with a large sampling interval.

3.
Med Mycol J ; 62(2): 29-34, 2021.
Article in English | MEDLINE | ID: mdl-34053977

ABSTRACT

Treatment of Candidemia has become increasingly complicated as more and more non-albicans Candida species are being isolated in recent years.We launched an investigation of the species, the MIC value, and the state of administration of antifungal drugs for all the cases with Candida spp. confirmed by blood cultures for the 7-year period from 2012 to 2018 at our hospital. In total, 192 cases were found and 206 strains of Candida species were isolated. Overall, 49.5% of the 206 isolated strains were Candida albicans (102 strains), followed by Candida glabrata (40 strains, 19.4%), and Candida parapsilosis (38 strains, 18.4%). The most frequently used antifungal drug for the initial dose was MCFG (120 cases, 59.2%), while the most frequently switched antifungal agent was L-AMB. Cases with an inappropriate end-of-treatment time represented 58.7% of all the cases.We investigated the Candidemia situation at our hospital for a period of seven years. We believe that it is important for medical institutions to gather detailed data on candidemia at their own hospitals. Likewise, the hospital's Infection Control Team/Antimicrobial Stewardship Team should inform the physicians-in-charge about the appropriate diagnosis and treatment based on the data obtained.


Subject(s)
Candidemia , Antifungal Agents/therapeutic use , Candida , Candidemia/drug therapy , Candidemia/epidemiology , Hospitals , Humans , Microbial Sensitivity Tests
5.
J Infect Chemother ; 27(2): 165-171, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32933858

ABSTRACT

INTRODUCTION: Aims of this study were (a) to assess the development ratio of hyponatremia during treatment with linezolid and (b) to evaluate the relationship between the risk of hyponatremia and linezolid exposure and patient background. METHOD: Clinical data including linezolid serum concentrations and serum sodium values were collected at Toyama University Hospital and Kyorin University Hospital. Data from 89 patients were used for the analysis, and a nadir serum sodium level ≤130 mmol/L during the treatment with linezolid was defined as hyponatremia. Mann-Whitney's U test was used to evaluate the effects of the area under the time-concentration curve (AUC) of linezolid at the nadir sodium level, clinical characteristics (e.g. laboratory data), and baseline serum sodium levels on the development of hyponatremia. RESULTS: The hyponatremia was occurred in 21 of 89 patients (23.6%). Data are compared for baseline and nadir serum sodium levels of patients with and without hyponatremia. In both groups, nadir serum sodium levels were significantly different from those of the baseline values (P < 0.05). The values of AUC0-12, accumulated AUC, baseline serum sodium levels and age were significantly different between patients with and without hyponatremia (P < 0.05). CONCLUSIONS: Linezolid exposure, age, and baseline sodium levels were detected as the risk factors for linezolid-related hyponatremia. Our findings suggest that regular monitoring of serum sodium levels is desirable during treatment with linezolid, especially for the elderly and patients with low serum sodium levels before the start of linezolid administration.


Subject(s)
Hyponatremia , Aged , Humans , Hyponatremia/chemically induced , Linezolid/adverse effects , Retrospective Studies , Risk Factors , Sodium
6.
Sci Rep ; 10(1): 8132, 2020 05 18.
Article in English | MEDLINE | ID: mdl-32424180

ABSTRACT

Some neural network can be trained by transfer learning, which uses a pre-trained neural network as the source task, for a small target task's dataset. The performance of the transfer learning depends on the knowledge (i.e., layers) selected from the pre-trained network. At present, this knowledge is usually chosen by humans. The transfer learning method PathNet automatically selects pre-trained modules or adjustable modules in a modular neural network. However, PathNet requires modular neural networks as the pre-trained networks, therefore non-modular pre-trained neural networks are currently unavailable. Consequently, PathNet limits the versatility of the network structure. To address this limitation, we propose Stepwise PathNet, which regards the layers of a non-modular pre-trained neural network as the module in PathNet and selects the layers automatically through training. In an experimental validation of transfer learning from InceptionV3 pre-trained on the ImageNet dataset to networks trained on three other datasets (CIFAR-100, SVHN and Food-101), Stepwise PathNet was up to 8% and 10% more accurate than finely tuned and from-scratch approaches, respectively. Also, some of the selected layers were not supported by the layer functions assumed in PathNet.

7.
Intern Med ; 57(13): 1855-1860, 2018 Jul 01.
Article in English | MEDLINE | ID: mdl-29491283

ABSTRACT

We herein report a case of simultaneous amebic colitis and cytomegalovirus (CMV) enteritis in an HIV-infected patient. The patient was a 40-year-old man who developed bloody stool and diarrhea. We diagnosed him with severe amebic colitis associated with HIV infection and administered metronidazole. While his symptoms began to improve, the patient then developed CMV enteritis. We administered ganciclovir, and his symptoms improved. However, despite control of the infection, stenosis of the descending colon caused intestinal obstruction, and colostomy was performed. This case shows the importance of considering the possibility of simultaneous infection when gastrointestinal symptoms appear in people infected with HIV.


Subject(s)
Antiviral Agents/therapeutic use , Colitis/surgery , Cytomegalovirus Infections/drug therapy , Dysentery, Amebic/drug therapy , Enteritis/surgery , Ganciclovir/therapeutic use , HIV Infections/complications , Adult , Colitis/complications , Colitis/diagnosis , Colitis/drug therapy , Colostomy , Cytomegalovirus Infections/complications , Dysentery, Amebic/complications , Enteritis/complications , Enteritis/drug therapy , Humans , Male , Treatment Outcome
8.
World J Methodol ; 6(1): 126-32, 2016 Mar 26.
Article in English | MEDLINE | ID: mdl-27019804

ABSTRACT

AIM: To seek the cause of Burkholderia cepacia complex (Bcc) infection outbreak and evaluate the efficacy of new methods for nebulizer maintenance. METHODS: We investigated the annual number of Bcc isolates recovered from clinical samples in our hospital between 1999 and 2013. Swab samples were randomly collected for bacterial culture before patient use from 10 each of the two machine types in August 2001; these included 20 samples from each of the following: Drain tubes, operating water chambers, oscillators, and nebulizing chambers. In addition, 10 samples each of nebulizer solutions before and after use were cultured. For environmental investigation, 10 samples were collected from sinks in the nurse stations of the wards where patients positive for Bcc were hospitalized. Numbers of Bcc isolates were compared before and after introduction of new methods for nebulizer maintenance in October 2001. In addition, randomly amplified polymorphic DNA (RAPD) assay was applied to find the genetic divergence of the Bcc isolates obtained from clinical samples and nebulizers. RESULTS: From January 1999 to December 2013, a total of 487 Bcc isolates were obtained from clinical specimens from 181 patients. Notably, 322 (66.1%) Bcc isolates were obtained from clinical specimens from 1999 to 2001, including 244 (115 patients) from sputum and 34 (11 patients) from blood. During this period, 14 isolates were obtained from nebulizer components. Among these, six were derived from nebulizer drain tubes, five from operating water chambers, and one from the oscillator before patient use, and two from nebulizer solutions after patient use. When Bcc was isolated from the nebulizer solution after patient use, Bcc was simultaneously detected in other parts of the nebulizer. Bcc was not isolated from any nebulizer solution before use. RAPD assays revealed similar DNA profiles in isolates obtained from patients and nebulizers. Investigation revealed damaged diaphragms in many nebulizers. The new maintenance methods for nebulizers, including restriction of the usage period, thorough disinfection, and routine check for diaphragm breakage, remarkably reduced Bcc isolation (165 isolates from patients in 12 years and 0 isolate from nebulizers in periodical sampling). In particular, Bcc has been isolated from blood from only one patient since the new methods were introduced. CONCLUSION: Appropriate maintenance of ultrasonic nebulizers is crucial for preventing Bcc contamination of nebulizers and subsequent respiratory tract and blood infections.

9.
Jpn J Antibiot ; 67(4): 223-32, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25420318

ABSTRACT

Antimicrobials are commonly used to treat acute respiratory tract infection in adults. Furthermore, their overuse has raised concern. We conducted a field survey study that included 170 medical institutions from January 2008 to June 2010. The purpose of this study was to clarify the relationship between the rate of antimicrobial use and patient outcomes with each indication. The study included 1753 patients diagnosed with acute respiratory tract infection. Antimicrobials were used for treatment of 1420 of these patients, whereas 333 cases were not treated with antimicrobials. After 3 days of treatment, patients administered antimicrobials experienced a higher improvement rate than those who did not receive antimicrobial treatment (92.2% vs. 83.3%, p < 0.0001). However, after 7 days of treatment, the rates of improvement for patients in both groups were similar (95.0% and 93.4%, respectively, p = 0.2391). In addition, according to the criteria for the usage of antimicrobials described in the Japanese Respiratory Society guidelines for the management of respiratory tract infection in adults, the patients were classified into the 3 categories (6 indication factors for antimicrobial use): Grade 1, ≤ 2 factors; Grade 2, 3-4 factors; Grade 3, 5-6 factors). The indication factors considered were the following: 1) temperature; 2) purulent sputum or nasal discharge; 3) tonsillar enlargement and tonsillolith/white puss; 4) middle otitis/sinusitis; 5) inflammatory reaction; and 6) high-risk patients. The results indicate that the improvement observed after 3 days of treatment in Grade 2 and Grade 3 patients was significantly higher with antimicrobial treatment than without antimicrobial treatment. In conclusion, the administration of antimicrobials is not recommended in younger patients with no underlying disease. However, the use of antimicrobials is required in patients with a higher relative risk that corresponds to the presence of ≥ 3 of the 6 indication factors for antimicrobial use.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Respiratory Tract Infections/drug therapy , Acute Disease , Aged , Anti-Bacterial Agents/adverse effects , Body Temperature , Female , Humans , Male , Middle Aged , Respiratory Tract Infections/physiopathology , Risk Factors
10.
BMJ Case Rep ; 20132013 Sep 25.
Article in English | MEDLINE | ID: mdl-24068515

ABSTRACT

A 29-year-old man with HIV infection was referred to our department because of a 1-month history of low-grade fever and fatigue. Bone marrow aspiration and biopsy showed findings consistent with haemophagocytic syndrome (HPS), and immunohistochemical assessment showed cytomegalovirus (CMV) infection. HIV-associated HPS can occur at any stages of HIV disease and requires diverse differential diagnosis. CMV-associated HPS (CMV-HPS) in patients with HIV infection is relatively rare, but the present case showed that the clinicians should consider the possibility of CMV-HPS as a clinical feature of CMV infection.


Subject(s)
AIDS-Related Opportunistic Infections/complications , Cytomegalovirus Infections/complications , Cytomegalovirus , Lymphohistiocytosis, Hemophagocytic/etiology , AIDS-Related Opportunistic Infections/diagnosis , Adult , Biopsy , Cytomegalovirus Infections/diagnosis , Diagnosis, Differential , Humans , Lymphohistiocytosis, Hemophagocytic/diagnosis , Male , Tomography, X-Ray Computed
11.
Am J Infect Control ; 41(9): 810-4, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23375577

ABSTRACT

BACKGROUND: The National Healthcare Safety Network transitioned from surgical site infection (SSI) rates to the standardized infection ratio (SIR) calculated by statistical models that included perioperative factors (surgical approach and surgery duration). Rationally, however, only patient-related variables should be included in the SIR model. METHODS: Logistic regression was performed to predict expected SSI rate in 2 models that included or excluded perioperative factors. Observed and expected SSI rates were used to calculate the SIR for each participating hospital. The difference of SIR in each model was then evaluated. RESULTS: Surveillance data were collected from a total of 1,530 colon surgery patients and 185 SSIs. C-index in the model with perioperative factors was statistically greater than that in the model including patient-related factors only (0.701 vs 0.621, respectively, P < .001). At one particular hospital, for which the percentage of open surgery was lowest (33.2%), SIR estimates changed considerably from 0.92 (95% confidence interval: 0.84-1.00) for the model with perioperative variables to 0.79 (0.75-0.85) for the model without perioperative variables. In another hospital with a high percentage of open surgery (88.6%), the estimate of SIR was decreased by 12.1% in the model without perioperative variables. CONCLUSION: Because surgical approach and duration of surgery each serve as a partial proxy of the operative process or the competence of surgical teams, these factors should not be considered predictive variables.


Subject(s)
Epidemiologic Methods , Infection Control/methods , Infection Control/standards , Surgical Wound Infection/epidemiology , Surgical Wound Infection/prevention & control , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged
12.
Jpn J Antibiot ; 66(6): 331-55, 2013 Dec.
Article in Japanese | MEDLINE | ID: mdl-24649798

ABSTRACT

From October 2006 to September 2007, we collected the specimen from 356 patients with lower respiratory tract infections in 14 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 414 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in infection, 407 strains were examined. The isolated bacteria were: Staphylococcus aureus 64, Streptococcus pneumoniae 96, Haemophilus influenzae 87, Pseudomonas aeruginosa (non-mucoid) 52, P. aeruginosa (mucoid) 11, Klebsiella pneumoniae 20, and Moraxella catarrhalis 44. Of 64 S. aureus strains, those with 2 microg/ml or less of MIC of oxacillin (methicillin-susceptible S. aureus: MSSA) and those with 4 microg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) were 27 (42.2%) and 37 (57.8%) strains, respectively. Against MSSA, imipenem had the most potent antibacterial activity and inhibited the growth of all strains at 0.063 microg/ml or less. Against MRSA, vancomycin and linezolid showed the most potent activity and inhibited the growth of all the strains at 1 microg/ml. Carbapenems showed the most potent activities against S. pneumoniae and in particular, panipenem inhibited the growth of all the strains at 0.063 microg/ml or less. Imipenem and faropenem also had a preferable activity and inhibited the growth of all the strains at 0.125 and 0.5 microg/ml, respectively. In contrast, there were high-resistant strains (MIC: over 128 microg/ml) for erythromycin (45.8%) and clindamycin (20.8%). Against H. influenzae, levofloxacin showed the most potent activity and its MIC90 was 0.063 microg/ml or less. Meropenem showed the most potent activity against P. aeruginosa (mucoid) and its MIC90 was 0.5 microg/ml. Against P. aeruginosa (non-mucoid), tobramycin had the most potent activity and its MIC90 was 2 microg/ml. Against K. pneumoniae, cefozopran was the most potent activity and inhibited the growth of all the strains at 0.063 microg/ml or less. Also, all the antibacterial agents except ampicillin generally showed a potent activity against M. catarrhalis and the MIC90 of them were 2 microg/ml or less. The approximately half the number (50.6%) of the patients with respiratory infection were aged 70 years or older. Bacterial pneumonia and chronic bronchitis accounted for 49.2% and 28.1% of all the respiratory infections, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. pneumoniae (29.2%), S. aureus (20.8%), and H. influenzae (12.9%). H. influenzae (25.0%) and P. aeruginosa (21.7%) also were frequently isolated from the patients with chronic bronchitis. Before the antibacterial agent administration, the bacteria frequently isolated from the patients were S. pneumoniae (27.5%) and H. influenzae (22.5%). The bacteria frequently isolated from the patients treated with macrolides was P. aeruginosa, and its isolation frequently was 39.4%.


Subject(s)
Bacteria/drug effects , Respiratory Tract Infections/microbiology , Bacteria/growth & development , Bacteria/isolation & purification , Drug Resistance, Bacterial , Humans , Microbial Sensitivity Tests
14.
Jpn J Antibiot ; 63(3): 242-54, 2010 Jun.
Article in Japanese | MEDLINE | ID: mdl-20976880

ABSTRACT

Yearly changes in the susceptibility of clinical isolates to ulifloxacin (UFX) and other fluoroquinolones were examined through surveys over 3 periods. In the first survey, 534 strains derived from 19 species were collected from clinical specimens during 6 months from December 2003 to May 2004. In the same way, 805 strains were collected from December 2005 to May 2006 in the second survey, and 863 strains were from December 2007 to May 2008 in the third survey. Over these 3 study periods, the susceptibilities of fluoroquinolones against methicillin-susceptible Staphylococcus aureus and Escherichia coli were decreased. The isolation frequency of levofloxacin-nonsusceptible strain was increased from 0% to 11.8% and from 14.6% to 20.8%, respectively. MIC90s of UFX against these pathogens were also increased, but its MIC90 for E. coli was 2 to 4 times lower than that of levofloxacin. On the other hand, the susceptibility of strains of Klebsiella pneumoniae to UFX was increased. Among the fluoroquinolones tested, UFX showed the most potent activity against Pseudomonas aeruginosa, and no changes in the MIC90s occurred during the surveillance. Although one strain of Streptococcus pneumoniae isolated in the third study period showed levofloxacin-resistance (MIC, 8 microg/mL), there were nearly no changes in the MIC90s of any agents tested including UFX against S. pneumoniae during the surveillance. As for other bacterial species, a tendency to increase in resistance to UFX was not observed. The activity of UFX against Salmonella spp. and Shigella spp. was superior/equal to those of fluoroquinolones tested.


Subject(s)
Anti-Bacterial Agents/pharmacology , Dioxolanes/pharmacology , Fluoroquinolones/pharmacology , Piperazines/pharmacology , Product Surveillance, Postmarketing , Bacteria/drug effects , Drug Resistance, Bacterial , Humans , Microbial Sensitivity Tests
15.
J Infect Chemother ; 16(4): 266-71, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20376684

ABSTRACT

Optimal management of steroid therapy for severe pneumonia is an urgent issue. One hundred forty-eight elderly patients enrolled in our study were treated for severe pneumonia in a university hospital in Tokyo from 1998 through 2002. Steroid drugs were given to 82 patients (55.4%), whereas 66 (44.6%) received no steroids. Based on this main division, retrospective analyses were performed with regard to patient characteristics, antimicrobial agents, use or nonuse of mechanical ventilators, and prognoses. Significant difference was not seen in age, sex, underlying disease, isolated pathogens, and artificial respirator between the steroid and nonsteroid groups. Partial pressure of oxygen in arterial blood/fraction of inspired oxygen (Pao(2)/Fio(2)) ratio was significantly lower in the steroid (227.2 +/- 96.9) compared with the nonsteroid group (271.6 +/- 86.4) (P < 0.01). Prognoses were evaluated 21 days after treatment initiation. Significant differences appeared: First, the average cure rate of patients who took steroids within 3 days after starting treatment was 62.7%, whereas the rate was 12.9% (P < 0.001) in those who did not take steroids earlier than the 4th day. The cure rate of the nonsteroid group was 39.3% (P < 0.001). Second, the total dose of steroids (methylprednisolone) given within 7 days was less in cured cases (774 +/- 749 mg) than in noncured cases (1,190 +/- 768 mg) (P < 0.05). In conclusion, steroids should be administered in the early stage after onset of pneumonia, and large doses of steroids becomes a compounding factor in the prognosis of pneumonia.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Pneumonia/drug therapy , Pregnadienetriols/therapeutic use , Aged , Aged, 80 and over , Chi-Square Distribution , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Pneumonia/diagnosis , Prognosis , Respiration, Artificial , Retrospective Studies
17.
J Med Microbiol ; 58(Pt 6): 697-705, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19429744

ABSTRACT

Although mycoplasmal pneumonia has been generally considered to be a disease with good prognosis, a pathogenic host immune response has been associated with its occurrence. In the present study, the pathogenic significance of the immune response was examined using germ-free mice either infected intranasally with Mycoplasma pneumoniae or inoculated with M. pneumoniae antigens (soluble antigen and partially purified antigen). In gnotobiotic mice monoassociated with M. pneumoniae, 10(4) c.f.u. M. pneumoniae per lung were isolated 2-28 days after infection. Inflammatory changes with infiltration of lymphocytes were histopathologically detected in the perivascular area at 2 and 7 days after infection. In the mice intranasally inoculated with soluble antigen or partially purified antigens (F6 and F10 antigens), infiltration of neutrophils and lymphocytes was histopathologically detected at 2 days after inoculation. Severe pneumonia with tissue destruction was observed in the mice inoculated with F6 antigen. A gamma interferon (IFN-gamma) dominant response in endogenous cytokine expression was observed in all the treated mice. These results indicate that inflammatory changes in the lung tissue were prolonged in gnotobiotic mice monoassociated with M. pneumoniae compared with mice inoculated with M. pneumoniae antigen. In addition, it was shown that IFN-gamma plays an important role in the pathogenesis of pneumonia in mice either infected with M. pneumoniae or inoculated with its antigen. In particular, the F6 antigen has been considered to be an important virulence factor in terms of induction of tissue injury causing infiltration of lymphocytes and neutrophils in the lung, suggesting a close interaction between the immune response and the occurrence of M. pneumoniae pneumonia.


Subject(s)
Germ-Free Life , Mycoplasma pneumoniae/pathogenicity , Pneumonia, Mycoplasma/immunology , Pneumonia, Mycoplasma/pathology , Animals , Antibodies, Bacterial/blood , Interferon-gamma/biosynthesis , Interleukin-4/biosynthesis , Lung/immunology , Lung/microbiology , Lung/pathology , Lymph Nodes/immunology , Lymphocytes/immunology , Mice , Mycoplasma pneumoniae/immunology , Mycoplasma pneumoniae/isolation & purification , Pneumonia, Mycoplasma/microbiology , Spleen/immunology , Spleen/pathology
18.
Jpn J Antibiot ; 61(4): 209-40, 2008 Aug.
Article in Japanese | MEDLINE | ID: mdl-19024644

ABSTRACT

From October 2005 to September 2006, we collected the specimen from 366 patients with lower respiratory tract infections in 12 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 411 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in infection, 406 strains were examined. The isolated bacteria were: Staphylococcus aureus 70, Streptococcus pneumoniae 85, Haemophilus influenzae 78, Pseudomonas aeruginosa (non-mucoid) 46, P. aeruginosa (mucoid) 14, Klebsiella pneumoniae 21, and Moraxella subgenus Branhamella catarrhalis 40. Of 70 S. aureus strains, those with 2 microg/ml or less of MIC of oxacillin (methicillin-susceptible S. aureus: MSSA) and those with 4 microg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) were 38 (54.3%) and 32 (45.7%) strains, respectively. Against MSSA, imipenem had the most potent antibacterial activity and inhibited the growth of 37 strains (97.4%) at 0.063 microg/ml or less. Against MRSA, arbekacin and vancomycin showed the most potent activity and inhibited the growth of all the strains at 1 microg/ml. Carbapenems showed the most potent activities against S. pneumoniae and in particular, panipenem inhibited the growth of all the strains at 0.063 microg/ml or less. Faropenem also had a preferable activity and inhibited the growth of all the strains at 0.25 microg/ml. In contrast, there were high-resistant strains (MIC: over 128 microg/ml) for erythromycin (38.1%) and clindamycin (22.6%). Against H. influenzae, levofloxacin showed the most potent activity and its MIC90 was 0.063 microg/ml or less. Meropenem showed the most potent activity against P. aeruginosa (mucoid) and its MIC90 was 0.5 microg/ml. Against P. aeruginosa (non-mucoid), arbekacin had the most potent activity and its MIC90 was 8 microg/ml. Against K. pneumoniae, cefozopran was the most potent activity and inhibited the growth of all the strains at 0.063 microg/ml or less. Also, all the antibacterial agents except ampicillin generally showed a potent activity against M. (B.) catarrhalis and the MIC90 of them were 2 microg/ml or less. The approximately half the number (53.6%) of the patients with respiratory infection were aged 70 years or older. Bacterial pneumonia and chronic bronchitis accounted for 44.3% and 29.8% of all the respiratory infection, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. aureus (15.4%), S. pneumoniae (23.4%), and H. influenzae (21.3%). S. aureus (25.4%) and S. pneumoniae (18.0%) also were frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from the patients were S. pneumoniae (22.0%) and H. influenzae (21.4%). The bacteria frequently isolated from the patients treated with macrolides were S. pneumoniae and P. aeruginosa, and their isolation frequencies were each 35.3%.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Respiratory Tract Infections/microbiology , Aged , Bacteria/isolation & purification , Bronchitis/microbiology , Drug Resistance, Bacterial , Haemophilus influenzae/drug effects , Haemophilus influenzae/isolation & purification , Humans , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Moraxella catarrhalis/drug effects , Moraxella catarrhalis/isolation & purification , Pneumonia, Bacterial/microbiology , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification , Sputum/microbiology , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/isolation & purification
19.
Aquat Toxicol ; 83(2): 126-33, 2007 Jun 15.
Article in English | MEDLINE | ID: mdl-17498819

ABSTRACT

Effects of tributyltin (TBT) which has been used for antifouling paint of ship's hulls and fishing nets on the immune system in Japanese flounder (Paralichthys olivaceus) were investigated. After short-term exposure to a high level of TBT, leucocytes in the head kidney from 1-year-old flounder were examined for the proportion of neutrophils in total leucocytes. Also examined were their respiratory burst activities using flow cytometry, the reduction of nitroblue tetrazolium (NBT) and lysozyme activities. Furthermore, long-term exposures to a relatively low level of TBT using young flounder were also carried out. The proportion of neutrophils in total leucocytes prepared from head kidney in each fish exposed to TBT at 20 microg/L for 5 days and the reduction of NBT by leucocytes prepared from the same experimental conditions increase compared to the control group. The contents were 42.0+/-6.8 and 52.5+/-6.3%, respectively. Significant differences of the NBT reduction were observed between 0 and 20 microg/L TBT exposure groups. On the other hand, the respiratory burst activity of cells in the exposure group clearly showed a tendency to decrease compared to the control group. Furthermore, high level of TBT also inhibited lysozyme activity which plays an important role for the bacteriocidal procedures. However, similar results were not obtained in the exposure group with a relatively low level of TBT. To determine the immunotoxic effects of TBT, infection experiments using pathogens which are naturally occurring should be further investigated.


Subject(s)
Flounder/immunology , Immune System/drug effects , Trialkyltin Compounds/toxicity , Water Pollutants, Chemical/toxicity , Animals , Environmental Exposure , Flow Cytometry , Kidney/drug effects , Leukocytes/drug effects , Muramidase/drug effects , Neutrophils/drug effects , Nitroblue Tetrazolium/metabolism , Phagocytes/drug effects , Respiratory Burst/drug effects , Trialkyltin Compounds/analysis
20.
Jpn J Antibiot ; 59(5): 323-54, 2006 Oct.
Article in Japanese | MEDLINE | ID: mdl-17180803

ABSTRACT

From October 2004 to September 2005, we collected the specimen from 319 patients with lower respiratory tract infections in 12 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 383 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 381 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 87, Streptococcus pneumoniae 80, Haemophilus influenzae 78, Pseudomonas aeruginosa (non-mucoid) 35, P. aeruginosa (mucoid) 9, Klebsiella pneumoniae 15, Moraxella subgenus Branhamella catarrhalis 30, etc. Of 87 S. aureus strains, those with 2 microg/mL or less of MIC of oxacillin (methicillin-sensitive S. aureus: MSSA) and those with 4 microg/mL or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) were 40 (46.0%) and 47 (54.0%) strains, respectively. Against MSSA, imipenem had the most potent antibacterial activity and inhibited the growth of all the strains at 0.063 microg/mL. Against MRSA, vancomycin showed the most potent activity and inhibited the growth of all the strains at 1 microg/mL. Arbekacin (ABK) also showed the potent activity and its MIC90 was 2 microg/mL. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5 microg/mL. Cefozopran (CZOP) also had a preferable activity (MIC90: 1 microg/mL) and inhibited the growth of all the strains at 2 microg/mL. In contrast, there were high-resistant strains (MIC: 128 microg/mL or more) for ABK (2.5%), erythromycin (37.5%), and clindamycin (38.8%). Against H. influenzae, levofloxacin showed the most potent activity and inhibited the growth of all the strains at 0.125 microg/mL. Meropenem showed the most potent activity against P. aeruginosa (mucoid) and inhibited the growth of all the strains at 2 microg/mL. Against P. aeruginosa (non-mucoid), amikacin (AMK) had the most potent activity and its MIC90 was 4 microg/mL. The activity of CZOP against the non-mucoid type also was preferable and its MIC90 was 8 microg/mL. Against K. pneumoniae, CZOP, cefmenoxime, cefpirome, flomoxef were the most potent activity and inhibited the growth of all the strains at 0.063 microg/mL. Also, all the agents generally showed a potent activity against M. (B.) catarrhalis and the MIC90 of them were 4 microg/mL or less. The approximately half the number (57.0%) of the patients with respiratory infection were aged 70 years or older. Bacterial pneumonia and chronic bronchitis accounted for 50.8% and 23.8% of all the respiratory infection, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. aureus (21.6%), S. pneumoniae (24.7%) and H. influenzae (20.1%). S. aureus (20.9%), S. pneumoniae (16.1%), and H. influenzae (16.1%) also were relatively frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from the patients were S. pneumoniae (22.3%) and H. influenzae (25.1%). The bacteria relatively frequently isolated from the patients treated with macrolides were P. aeruginosa and the isolation frequency was 43.5%.


Subject(s)
Bacteria/drug effects , Bronchial Diseases/microbiology , Drug Resistance, Bacterial , Lung Diseases/microbiology , Aged , Bacteria/isolation & purification , Haemophilus influenzae/drug effects , Haemophilus influenzae/isolation & purification , Humans , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Moraxella catarrhalis/drug effects , Moraxella catarrhalis/isolation & purification , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...